Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth
- 1 December 1995
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 102 (3) , 468-475
- https://doi.org/10.1111/j.1365-2249.1995.tb03839.x
Abstract
SUMMARY: Immunosuppressive retrovirus-related proteins, like p15E, are involved in tumour-associated immunosuppression. In the present study we investigated whether such proteins could be used as targets in tumour immunotherapy using MoAbs. Immunotherapy was performed in mice inoculated with the Rauscher virus-transformed myeloid cell line RMB-1. RMB-1 cells express retroviral antigens at their cell surface. In order to obtain constant scrum titres of MoAbs over a prolonged period of time during therapy, anti-pl 5E antibody-producing hybridoma ceils were encapsulated in alginate and injected intraperitoneally in tumour-bearing mice. Using this technique, serum antibody titres of 50–100μg/ml were obtained, which remained constant over a period of at least 3 weeks. Therapy experiments were performed using anti-p15E antibodies 1F8, which recognizes both cell surface-associated as well as circulating pi 5E. and ER-1S5, which did not react with surface-bound p15E beyond background, but which neutralizes circulating p15E. Inoculation of alginates containing anti-p15E hybridoma cell lines in RMB-1 tumour-bearing mice showed inhibition of tumour cell growth. In survival experiments, 19F8 cured eight of 23 tumour-bearing mice. The p 15E neutralizing antibody ER-IS5 caused a significant longer survival, but therapy with this MoAb alone was not sufficient to cure the animals of the RMB-1 tumour.Keywords
This publication has 30 references indexed in Scilit:
- Antiinflammatory effects of neoplasmsResearch in Immunology, 1993
- The presence of immunosuppressive ‘p15E-like’ factors in the serum and urine of patients suffering from malign and benign breast tumoursClinical and Experimental Immunology, 1993
- Immunosuppression by retroviral-envelope-related proteins, and their role in non-retroviral human diseaseCritical Reviews in Oncology/Hematology, 1993
- Distribution of retroviral p15E-related proteins in neoplastic and non-neoplastic human tissues, and their role in the regulation of the immune responseClinical and Experimental Immunology, 1992
- Continuous Production of Monoclonal Antibody by Hybridoma Cells Immobilized in Hardened Alginate Gel ParticlesAnnals of the New York Academy of Sciences, 1990
- Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: Immunosuppression, immunogenicity, and relation to immunosuppressive tumor productsCancer Immunology, Immunotherapy, 1989
- Syngeneic monoclonal antibodies directed against rauscher virusinduced myeloid leukemic cells: Isolation and characterizationInternational Journal of Cancer, 1988
- Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cellsInternational Journal of Cancer, 1988
- Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses.Journal of Clinical Investigation, 1981
- DMSO-induced terminal differentiation and trisomy 15 in myeloid cell line transformed by the Rauscher murine leukemia virusCell Differentiation, 1981